Literature DB >> 17987806

Association of B-chronic lymphocytic leukemia and acute myeloid leukemia.

G Carulli1, A Marini, E Baccelli, P Lambelet, T Lari, A Azzarà.   

Abstract

A 62-year-old man presented with fatigue, pallor and mild weight loss. Laboratory studies showed Hb 7.6 g/dl, Hct 21.8%, WBC 108x10(9)/1, PLT 143x10(9)/1. At morphological examination, circulating cells appeared as 60% blasts and 40% lymphocytes, with smudge cells. A bone marrow aspirate showed infiltration by blasts (50%) and lymphocytes (40%); alpha-naphtyl-acetate esterase was positive in 90% of blasts, while myeloperoxidase was positive in 10%. The immunologic phenotype of blasts was characterized by the co-expression of CD13, CD33, CD14, CD4, CD15, CD64, CD117, HLA-DR, CD11b. Lymphocytes were characterized by a B-CLL immunophenotype: CD19+, CD5+, CD23+, CD20+(dim), FMC7+(dim), K light chain+(dim). Karyotype was normal and PCR assays for AML-ETO, CBFbeta-MYH11, PML-RARalpha, BCR-ABL and bcl-1/JH translocation were negative. Coexistence of CLL and AML with monoblastic features was diagnosed. Simultaneous appearance of CLL and AML has rarely been described and represents a peculiar biological phenomenon.

Entities:  

Mesh:

Year:  2007        PMID: 17987806

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  2 in total

1.  Concurrent presentation of nodal myeloid sarcoma and bone marrow chronic lymphocytic leukemia/small lymphocytic lymphoma: a unique association.

Authors:  Vasilios Perifanis; Michael D Diamantidis; Kyriaki Chalvatzi; Vassiliki Kaloutsi; Dimitra Markala; Virginia Voulgaridou; Pavlina Pantelidou; Athinodoros Pavlidis; George Stavrou; Georgia Kaiafa
Journal:  Int J Hematol       Date:  2014-02-07       Impact factor: 2.490

2.  Rare Coexistence of Acute Monoblastic Leukemia with Chronic Lymphocytic Leukemia.

Authors:  Vikrant Singh Bhar; Vasudha Gupta; Mahak Sharma; Rishi Dhawan; Shilpi Modi; Mona Vijyaran
Journal:  Case Rep Hematol       Date:  2018-11-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.